Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13884657 | 1.00 | CA12 (0.38) | CA12CA1CA9PSMD10ALDH1A1 | |
| SCHEMBL31556805 | 1.00 | CA12 (0.38) | CA12CA1CA9PSMD10ALDH1A1 | |
| SCHEMBL18301202 | 1.00 | CA12 (0.38) | CA12CA1CA9PSMD10ALDH1A1 | |
| SCHEMBL31556837 | 1.00 | CA12 (0.38) | CA12CA1CA9PSMD10ALDH1A1 | |
| SCHEMBL15881370 | 1.00 | CA12 (0.38) | CA12CA1CA9PSMD10ALDH1A1 | |
| SCHEMBL15264830 | 1.00 | CA12 (0.38) | CA12CA1CA9PSMD10ALDH1A1 | |
| SCHEMBL26634633 | 1.00 | CA12 (0.38) | CA12CA1CA9PSMD10ALDH1A1 | |
| SCHEMBL16599488 | 0.98 | CA12 (0.39) | CA12CA1CA9PSMD10ALDH1A1 | |
| SCHEMBL14363642 | 0.94 | CA12 (0.40) | CA12CA1CA9PSMD10ALDH1A1 | |
| SCHEMBL13456779 | 0.88 | CA12 (0.41) | CA12CA1CA9PSMD10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743069-B1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BIOVENTURES LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250236607-A1 | CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2025-07-24 | — | — | US | disclosed |
| WO-2025075958-A1 | POLYMER-FUNCTIONALIZED RETICULAR MATERIALS FOR CARBON DIOXIDE CAPTURE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4499148-A1 | CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF | Ohio State Innovation Foundation (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12118414-B2 | BCL-2 proteins degraders for cancer treatment | BIOVENTURES, LLC (US) | 2024-10-15 | — | — | US | disclosed |
| WO-2023192534-A1 | CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-112105360-A | BCL-2 protein degrading agents for cancer treatment | 生物风险投资有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3743069-A1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BioVentures, LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2020168172-A1 | CONJUGATE COMPOUNDS FOR THE DEGRADATION OF RAF | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2020-08-20 | — | — | WO | disclosed |
| WO-2019144117-A1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BIOVENTURES, LLC (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12118414-B2 | BCL-2 proteins degraders for cancer treatment | BCL2, BCL2L1, BCL2L2 | CA12 3781/4885CA1 4443/4885CA9 4062/4885 |
| US-20250236607-A1 | CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF | CDK9, CDK19, CDKL2 | CA12 3413/4885CA1 3914/4885CA9 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.